

Vaccines and Systemic Therapies Quick Reference Chart

Drug	Non-Live Vaccine	Live Vaccine
Methotrexate	Consider delaying dose for 2 weeks after vaccination	Consider discontinuing for 2-4 weeks prior and hold for 2-4 weeks after vaccine
Cyclosporine	No change	Defer next cyclosporine dose until 2-4 weeks after vaccine
Acitretin	No change	No change
Apremilast	No change	No change
TNF-α blocker	No change	Discontinue for 2-3 half lives prior to vaccine, defer next dose until 2-4 weeks after vaccine
IL-12/23 antagonist	No change	Discontinue for 2-3 half lives prior to vaccine, defer next dose until 2-4 weeks after vaccine
IL-17 antagonist	No change	Discontinue for 2-3 half lives prior to vaccine, defer next dose until 2-4 weeks after vaccine
IL-23 antagonist	No change	Discontinue for 2-3 half lives prior to vaccine, defer next dose until 2-4 weeks after vaccine
Tofacitinib	No change	Hold for 1 week prior to vaccine, defer next dose until 2-4 weeks after vaccine
Deucravacitinib	No change	Discontinue for 1 day (2-3 half lives) prior to vaccine, defer next dose until 2-4 weeks after vaccine
Common examples	COVID-19, Haemophilus influenzae type b (Hib), hep B, injectable influenza, pneumococcal (PCV13, PPSV23, PCV 10, PCV15), recombinant herpes zoster (Shingrix), tetanus toxoid (diphtheria-tetanus-pertussis, tetanus-diphtheria toxoid)	BCG, intranasal influenza, live zoster (Zostavax), MMR, yellow fever, smallpox, mpox
Clinical Consideration	Possible concern for blunted immune response to vaccine	Possible concern for virus reactivation and infection from vaccine

BCG=Bacillus Calmette–Guérin vaccine

Reference: Chat VS, Ellebrecht CT, Kingston P, et al. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. *J Am Acad Dermatol.* 2024;90(6):1170-1181. doi:10.1016/j.jaad.2023.12.070